BMS Expands Radiopharma Presence With $1.35B Biobucks Deal for Philochem

Instead of homing in on PSMA—currently the most validated target in prostate cancer—BMS and Philochem will instead collaborate on an early-stage molecule that binds to a novel marker called ACP3.